Physician profile
Mark Lott
NPI 1821192139
$7,800.26
in general payments reported to CMS, 2019-2025
15 companies · $2,157 in 2025
The $2,157 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $672 · 2021: $1,666 · 2022: $1,401 · 2023: $855 · 2024: $672 · 2025: $2,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017 · Grant: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.73 |
| Grant | $1,666.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,239.90 | 2019-2025 | Xifaxan, Plenvu |
| Abbvie INC. | $1,729.26 | 2019-2025 | |
| Madrigal Pharmaceuticals | $1,714.11 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $726.22 | 2019-2025 | |
| Pfizer INC. | $468.11 | 2019-2025 | |
| Janssen Biotech, INC. | $335.43 | 2021-2023 | Stelara, Remicade, Simponi |
| Braintree Laboratories, INC. | $190.90 | 2020-2024 | Sutab, Suflave |
| Genzyme Corporation | $123.95 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $81.53 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $49.29 | 2025 | Zenpep |
| Redhill Biopharma INC. | $44.12 | 2021-2025 | Talicia |
| Qol Medical, LLC | $36.19 | 2021 | |
| Ambu INC. | $31.04 | 2021 | |
| Merck Sharp & Dohme LLC | $16.21 | 2019 | |
| Celltrion USA INC. | $14.00 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.